Aptevo leans on TP53 leukaemia signal as it eyes 2027 regulators with $8.3m in cash
Early RAINIER data for mipletamig plus venetoclax and azacitidine give the small-cap a story to take to regulators, but its balance sheet remains thin.
Aptevo Therapeutics is pointing to a response signal in one of acute myeloid leukaemia's hardest genetic subgroups as it tries to move mipletamig towards a regulatory conversation. The company's third-quarter update, dated 16 November 2026, paired its financial results with fresh data from the Phase 1b RAINIER study in frontline AML.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.